22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
I have discussed in the past how the use of “no-rehire” provisions in settlement agreements betwee...
Read More >
Let’s face it: the majority of law graduates around the world, including myself once upon a time, s...
Read More >
The energy and chemicals industries play a central role in our economy and regularly capture the att...
Read More >
A recent case in the Tenth Circuit Court of Appeals addresses the intersection of Employee Stock Own...
Read More >
FHA recently announced the issuance of its long-anticipated final rule allowing Project Approval for...
Read More >
A new package of pro-employee laws regarding worker misclassification in New Jersey was recently sig...
Read More >